Cargando…

Factor-XIII activity in patients with mild to moderate ulcerative colitis and active bleeding: a prospective observational study

OBJECTIVE: Coagulation factor XIII plays a key role in fibrin clot stabilization and epithelial healing. Under chronic inflammatory conditions involving bleeding and an activation of the coagulation cascade, the FXIIIa inversely correlate with disease activity. We assumed that FXIIIa could be a pred...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bernerth, Karsten, Schiefke, Ingolf, Liebscher, Karin, Raczynski, Susanne, Kottmann, Tanja, Teich, Niels
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research Note
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6278029/ https://www.ncbi.nlm.nih.gov/pubmed/30514356 http://dx.doi.org/10.1186/s13104-018-3963-8

Ejemplares similares

Medical Therapy of Active Ulcerative Colitis
por: Bürger, Martin, et al.
Publicado: (2015)

Usage characteristics and adverse event rates of the direct puncture and pull techniques for percutaneous endoscopic gastrostomy in patients with malignant tumors of the upper aerodigestive tract
por: Teich, Niels, et al.
Publicado: (2018)

Refractory Duodenal Bleeding Ulcers Successfully Treated with Factor XIII Transfusion
por: Yamada, Yusuke, et al.
Publicado: (2021)

The inverse starving test is not a suitable provocation test for Gilbert's syndrome
por: Teich, Niels, et al.
Publicado: (2008)

The Hole in the Stomach
por: Bödeker, Hans, et al.
Publicado: (2008)

Health-Related Quality of Life in Chinese Patients with Mild and Moderately Active Ulcerative Colitis
por: Zheng, Kai, et al.
Publicado: (2015)

International Consensus on Definition of Mild-to-Moderate Ulcerative Colitis Disease Activity in Adult Patients
por: Caron, Bénédicte, et al.
Publicado: (2023)

Key Strategies to Optimize Outcomes in Mild-to-Moderate Ulcerative Colitis
por: Solitano, Virginia, et al.
Publicado: (2020)

Mild to moderate ulcerative colitis: Call me by my name
por: Rodríguez‐Lago, Iago, et al.
Publicado: (2022)

Golimumab improves work productivity in patients suffering from moderate to severe ulcerative colitis: results of a prospective study over 24 months
por: Teich, Niels, et al.
Publicado: (2021)

High- and Low-Dose Oral Delayed-Release Mesalamine in Children With Mild-to-Moderately Active Ulcerative Colitis
por: Winter, Harland S., et al.
Publicado: (2014)

Once-daily MMX mesalamine for the treatment of mild-to-moderate ulcerative colitis
por: Kedia, Prashant, et al.
Publicado: (2007)

Ulcerative Colitis-Symptom Questionnaire: Valid for Use in Adults with Moderately to Severely Active Ulcerative Colitis
por: Panes, Julian, et al.
Publicado: (2023)

Golimumab in real-world practice in patients with ulcerative colitis: Twelve-month results
por: Teich, Niels, et al.
Publicado: (2020)

Differences in bleeding behavior after endoscopic band ligation: a retrospective analysis
por: Petrasch, Florian, et al.
Publicado: (2010)

Mesalazine granules promote disease clearance in patients with mild‐to‐moderate ulcerative colitis
por: Kruis, Wolfgang, et al.
Publicado: (2023)

Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study
por: Travis, Simon P L, et al.
Publicado: (2014)

Safety and Potential Role of Lactobacillus rhamnosus GG Administration as Monotherapy in Ulcerative Colitis Patients with Mild–Moderate Clinical Activity
por: Pagnini, Cristiano, et al.
Publicado: (2023)

Modelling the benefits of an optimised treatment strategy for 5-ASA in mild-to-moderate ulcerative colitis
por: Louis, Edouard, et al.
Publicado: (2022)

Definition of mild to moderate ulcerative colitis in clinical trials: A systematic literature review
por: Caron, Bénédicte, et al.
Publicado: (2022)

Fecal microbiota transplantation versus glucocorticoids for the induction of remission in mild to moderate ulcerative colitis
por: Huang, Chunlan, et al.
Publicado: (2022)

Mild-to-Moderate Ulcerative Colitis: Your Role in Patient Compliance and Health Care Costs
por: Tindall, William N., et al.
Publicado: (2007)

Treatment of Patients with Mild to Moderate Ulcerative Colitis: A Middle East Expert Consensus
por: Awadhi, Sameer Al, et al.
Publicado: (2023)

Medication Formulation Preference of Mild and Moderate Ulcerative Colitis Patients: a European Survey
por: Hébuterne, Xavier, et al.
Publicado: (2023)

Understanding the Role of Adalimumab in the Treatment of Moderately to Severely Active Ulcerative Colitis
por: Kim, Jae Hyun, et al.
Publicado: (2016)

Efficacy of oral prolonged‐release mesalazine in moderately active ulcerative colitis
por: Paridaens, Kristine, et al.
Publicado: (2023)

Chinese Patent Medicine as Adjuvant for Mild-to-Moderate Active Ulcerative Colitis: A Network Meta-Analysis of Randomized Controlled Trials
por: Sun, Yu-Xin, et al.
Publicado: (2021)

Use of Faecal Transplantation with a Novel Diet for Mild to Moderate Active Ulcerative Colitis: The CRAFT UC Randomised Controlled Trial
por: Sarbagili Shabat, Chen, et al.
Publicado: (2021)

Budesonide MMX for the Induction of Remission of Mild to Moderate Ulcerative Colitis: A Pooled Safety Analysis
por: Lichtenstein, Gary R., et al.
Publicado: (2015)

Vitamin D Status and Its Relation to Inflammatory Markers in Patients with Mild to Moderate Ulcerative Colitis
por: Sharifi, Amrollah, et al.
Publicado: (2018)

Vitamin D Increases CTLA-4 Gene Expression in Patients with Mild to Moderate Ulcerative Colitis
por: Sharifi, Amrollah, et al.
Publicado: (2019)

The impact of clinical experience on decision-making regarding the treatment and management of mild-to-moderate ulcerative colitis
por: Cheon, Jae Hee, et al.
Publicado: (2023)

Assessing Colonic Exposure, Safety, and Clinical Activity of SRT2104, a Novel Oral SIRT1 Activator, in Patients with Mild to Moderate Ulcerative Colitis
por: Sands, Bruce E., et al.
Publicado: (2015)

Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis
por: Suzuki, Yasuo, et al.
Publicado: (2013)

Exposure‐response relationships of etrolizumab in patients with moderately‐to‐severely active ulcerative colitis
por: Kassir, Nastya, et al.
Publicado: (2022)

Population pharmacokinetic analysis of etrolizumab in patients with moderately‐to‐severely active ulcerative colitis
por: Moein, Anita, et al.
Publicado: (2022)

Cost Effectiveness of Tofacitinib for the Treatment of Moderate to Severe Active Ulcerative Colitis in Colombia
por: Gil, Fabio, et al.
Publicado: (2022)

Update on the role of upadacitinib in the treatment of adults with moderately to severely active ulcerative colitis
por: Ernest-Suarez, Kenneth, et al.
Publicado: (2023)

Combined Diosmectite and Mesalazine Treatment for Mild-to-Moderate Ulcerative Colitis: A Randomized, Placebo-Controlled Study
por: Jiang, Xue-Liang, et al.
Publicado: (2015)

Is once daily multimatrix mesalazine therapy effective regardless of the dose in patients with mild to moderate ulcerative colitis?
por: Jeon, Seong Ran
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_dos8a385ulochsbnh5vfpksppk